Last reviewed 2026-04-20 · How we verify

TILD

Tild is a small molecule that works by interacting with a specific target in the body.

Tild is a small molecule drug developed by Sun Pharmaceutical Industries Limited. However, there is limited information available about its target, drug class, and approved indications. As a result, it is difficult to provide a comprehensive summary of its mechanism of action and clinical use. Further research is needed to understand the properties and potential applications of tild. Its commercial status and safety considerations also remain unclear.

At a glance

Mechanism of action

Imagine your body's cells have locks on them, and tild is a key that fits into one of those locks. When tild binds to its target, it can either block or enhance the activity of that target, which can help to treat a particular disease or condition. This is a simplified explanation of how small molecules like tild work.

Approved indications

• Plaque psoriasis

Common side effects

• Upper respiratory infections
• Injection site reactions
• Diarrhea
• Dizziness
• Pain in extremity

Serious adverse events

• Angioedema
• Urticaria

Key clinical trials

• Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) (PHASE3)
• Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis (PHASE3)
• Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TILD CI brief — competitive landscape report
• TILD updates RSS · CI watch RSS
• Sun Pharmaceutical Industries Limited portfolio CI